Patients Physicians Safety 
World of DTC Marketing
MARCH 23, 2022
Accelerated Approval allows for early access to drugs and biologics based on initial evidence of safety and effectiveness, while confirmatory studies required to verify clinical benefits are ongoing. Do patients care? The program was codified into law under the Food and Drug Safety and Innovation Act (FDASIA) in 2012.
Nixon Gwilt Law
JULY 23, 2024
In the recently released 2025 Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”), the Centers for Medicare & Medicaid Services (CMS) created a new reimbursement pathway for “Digital Mental Health Treatment” (DMHT) devices and services.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
OCTOBER 11, 2023
To address the growing physician shortage, some people argue that the scope of practice should be expanded for skilled healthcare professionals like nurse practitioners and pharmacists. He argued that throwing other professionals into physicians’ roles will have poor ramifications of patient safety.
Celeritas
SEPTEMBER 26, 2022
A) Aiding Healthcare Professionals (HCPs): Storage of Patient Information: The common method of use of QR codes is in the organization and accessibility of patient records. In essence, patients’ files are all synced to a medical database. They’re ideal for monitoring elderly patients who tend to wander off or sleepwalk.
Pharmaceutical Technology
APRIL 11, 2023
Oracle company Cerner Enviza and John Snow Labs have collaborated with the US Food and Drug Administration (FDA) for the development of artificial intelligence (AI) tools for drug safety and real-world evidence studies.
Nixon Gwilt Law
JULY 23, 2024
In the recently released 2025 Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”), the Centers for Medicare & Medicaid Services (CMS) created a new reimbursement pathway for “Digital Mental Health Treatment” (DMHT) devices and services.
European Pharmaceutical Review
OCTOBER 25, 2022
AstraZeneca’s Imfinzi (durvalumab) and Imjudo (tremelimumab) combination therapy has been approved in the US for adult patients with unresectable hepatocellular carcinoma (HCC). Phase III trial results found that three years post-treatment, 31 percent of patients given the drug combination were still alive.
Expert insights. Personalized for you.
200 
Let's personalize your content